Nuveen’s Harvard Bioscience HBIO Stock Holding History

Nuveen’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-14,000	Closed	-$79.2K	–	3317
2025 Q1	$79.2K	Hold	14,000	–	–	﹤0.01%	3235
2024 Q4	$295K	Hold	14,000	–	–	﹤0.01%	3132
2024 Q3	$377K	Hold	14,000	–	–	﹤0.01%	3096
2024 Q2	$399K	Hold	14,000	–	–	﹤0.01%	3067
2024 Q1	$594K	Hold	14,000	–	–	﹤0.01%	2919
2023 Q4	$749K	Hold	14,000	–	–	﹤0.01%	2853
2023 Q3	$602K	Hold	14,000	–	–	﹤0.01%	2781
2023 Q2	$769K	Buy	+14,000	New	+$768K	﹤0.01%	2771
2022 Q2	–	Sell	-10,118	Closed	-$600K	–	3353
2022 Q1	$600K	Buy	10,118 +1,017	+11%	+$60.2K	﹤0.01%	2958
2021 Q4	$631K	Sell	9,101 -2,745	-23%	-$195K	﹤0.01%	3006
2021 Q3	$907K	Sell	11,846 -570	-5%	-$45.4K	﹤0.01%	3020
2021 Q2	$1.03M	Sell	12,416 -5,082	-29%	-$360K	﹤0.01%	2991
2021 Q1	$955K	Sell	17,498 -800	-4%	-$38.9K	﹤0.01%	2894
2020 Q4	$785K	Buy	18,298 +179	+1%	+$6.68K	﹤0.01%	2892
2020 Q3	$545K	Buy	18,119 +2,418	+15%	+$81.3K	﹤0.01%	2928
2020 Q2	$487K	Buy	+15,701	New	+$423K	﹤0.01%	2908

Other funds holding HBIO

AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

MIM

Meros Investment Management Dallas, Texas $231M AUM 35.94% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nuveen's HBIO Position: Q2 2025 in Review

Nuveen sold out of Harvard Bioscience (HBIO) in Q2 2025, closing a stake of 14,000 shares — an estimated $79.2K sold.

Nuveen first reported a position in HBIO in Q2 2020 and held it in 16 quarters. The position peaked at $1.03M in Q2 2021. 68 funds tracked by Wall St. Rank hold HBIO as of Q2 2025.

Nuveen reported no remaining Harvard Bioscience position as of Q2 2025 after selling out during the quarter.
Nuveen sold 14,000 Harvard Bioscience shares in Q2 2025, an estimated $79.2K.
Nuveen first reported a position in Harvard Bioscience in Q2 2020 and held it in 16 quarters.
Nuveen's Harvard Bioscience position peaked at $1.03M in Q2 2021.
68 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2025.

Based on Nuveen's 13F filing for Q2 2025, filed 12 Aug 2025.